Status:
COMPLETED
Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
Brief Summary
To investigate the safety and efficacy of long-term use of Prazaxa® Capsules in patients with nonvalvular atrial fibrillation for preventing the occurrence of ischemic stroke or systemic embolism (SEE...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- Patients with nonvalvular atrial fibrillation who have never received Prazaxa Capsules for preventing the occurrence of ischemic stroke and systemic embolism will be included.
- Exclusion criteria:
- \- None
Exclusion
Key Trial Info
Start Date :
December 12 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 2 2016
Estimated Enrollment :
6772 Patients enrolled
Trial Details
Trial ID
NCT01491178
Start Date
December 12 2011
End Date
August 2 2016
Last Update
January 30 2018
Active Locations (1164)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 1
Abashiri, Hokkaido, Japan
2
Boehringer Ingelheim Investigational Site 287
Adachi,Tokyo, Japan
3
Boehringer Ingelheim Investigational Site 288
Adachi,Tokyo, Japan
4
Boehringer Ingelheim Investigational Site 289
Adachi,Tokyo, Japan